MASTER COLLABORATION AGREEMENT by and among PROTHENA BIOSCIENCES LIMITED And CELGENE SWITZERLAND LLC Dated as of March 20, 2018Master Collaboration Agreement • May 9th, 2018 • Prothena Corp PLC • Pharmaceutical preparations • New York
This MASTER COLLABORATION AGREEMENT (this “Agreement”) is entered into and made effective as of March 20, 2018 (the “Effective Date”) by and among Prothena Biosciences Limited, an Irish limited company (“Prothena”) and Celgene Switzerland LLC, a Delaware limited liability company (“Celgene”). Celgene and Prothena are each referred to herein by name or as a “Party”, or, collectively, as the “Parties”.
LICENSE AGREEMENT BETWEEN NEOTOPE BIOSCIENCES LIMITED AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA FOR CASE NO. SD2002-035License Agreement • May 9th, 2018 • Prothena Corp PLC • Pharmaceutical preparations • California
This agreement (“Agreement”) is made by and between NEOTOPE BIOSCIENCES LIMITED, a private limited company incorporated under the laws of Ireland with offices at 25- 28 North Wall Quay, Dublin 1, Ireland (“LICENSEE”) and The Regents of the University of California, a California corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (“UNIVERSITY”), represented by its San Diego campus having an address at University of California, San Diego, Technology Transfer Office, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (“UCSD”).
SHARE SUBSCRIPTION AGREEMENT By and Between Celgene Switzerland LLC and Prothena Corporation plc Dated as of March 20, 2018Share Subscription Agreement • May 9th, 2018 • Prothena Corp PLC • Pharmaceutical preparations • New York
THIS SHARE SUBSCRIPTION AGREEMENT (the “Agreement”) is made and entered into as of March 20, 2018 (the “Signing Date”), by and between Prothena Corporation plc, an Irish public limited company (the “Company”), and Celgene Switzerland LLC, a Delaware limited liability company (the “Subscriber”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 9th, 2018 • Prothena Corp PLC • Pharmaceutical preparations • New York
This Exclusive License Agreement (“Agreement”; and as further defined herein) is made effective as of July 25, 2016 (the “Effective Date”) between:
LICENSE AGREEMENT AMENDMENT NUMBER ONELicense Agreement • May 9th, 2018 • Prothena Corp PLC • Pharmaceutical preparations
This License Agreement Amendment Number One (the “Amendment”) is made as of January 15, 2014 (the “Amendment Effective Date”) by and between Neotope Biosciences Limited, a private limited company incorporated under the laws of Ireland with offices at 25-28 North Wall Quay, Dublin 1, Ireland (“LICENSEE”) and The Regents of the University of California, a California corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (“UNIVERSITY”), represented by its San Diego campus having an address at University of California, San Diego, Technology Transfer Office, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (“UCSD”).
